article thumbnail

ElevateBio and Affini-T collaborate to develop T cell therapies

Pharmaceutical Technology

Affini-T’s platform can choose and engineer the correct immune cells to create a lasting and coordinated immune response in the immunosuppressive tumour microenvironment. To act on oncogenic driver mutations, Affini-T is using engineered T-cell therapies with synthetic biology and gene editing enhancements.

article thumbnail

Gene Therapy and Pharmacokinetics

Camargo

Gene therapy is a new therapeutic approach in which genes are used to treat or prevent diseases. It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vycellix CEO to Present its Universal Cell Program (VY-UC) for Off-the-Shelf NK Cell Therapy at Allogeneic Cell Therapies Summit

BioTech 365

-Proof-of-concept achieved for VY-UC to engineer donor cells without the complexities of gene-editing -Novel platform abrogates cellular immune response and obviates the need for immunosuppressive drugs TAMPA, Fla. & & STOCKHOLM–(BUSINESS WIRE)–#celltherapy–Vycellix, Inc.,

article thumbnail

FDA fast tracks type 1 diabetes cell therapy from Vertex

pharmaphorum

That is an approach that has been tried in other groups, but so far efforts have been impeded by difficulties in producing enough cells of sufficient quality and protecting them from the patient’s immune response. That implantable technology was at the heart of the Semma acquisition.

article thumbnail

How Researchers Stumbled Upon an Arthritis Vaccine Just in Time for World Arthritis Day

XTalks

The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease. is an autoantigen, which means it is an endogenous antigen that triggers an immune response in the body. as a potential trigger for rheumatoid arthritis.

article thumbnail

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

XTalks

These findings signify a significant step forward in the development of AGT103-T as a potential gene therapy for HIV. In 2021, the FDA granted approval to San Francisco-based Excision BioTherapeutics to start trials assessing CRISPR gene editing as a potential treatment for HIV. In November 2023, Hookipa Pharma Inc.,

article thumbnail

Are We Getting Closer to a Herpes Vaccine?

The Pharma Data

The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. As Pickard explained, one issue is that some candidate vaccines use only a subset of HSV components, or antigens, to try to generate an immune response. MONDAY, Nov.